TrialFinder  /  Landscape Report DIABETES  ·  2026-09-03 Revasser  /  revasserkernel.com
Landscape Report TrialFinder
SOURCE  ClinicalTrials.gov API v2
GENERATED  2026-09-03
VERSION  v1
SAMPLE  100 of 7058 studies

diabetes

The diabetes clinical trial landscape includes 7058 actively recruiting trials. Semantic expansion identified 5123 additional trials beyond exact-match search, representing a 264.8% discovery lift across related conditions and therapeutic approaches.

Recruiting
7058
active trials
Expansion Lift
+264.8%
5123 additional trials
Top Sponsor
Novo Nordisk A/S
3 trials
Dominant Phase
NA
37 of 104 sampled
Pipeline Overview
Phase Distribution
NA
37
Early I
2
Phase 1
10
Phase 2
18
Phase 3
3
Phase 4
3
Other
31
Therapeutic Modalities
DRUG
83
OTHER
31
BEHAVIORAL
25
DEVICE
9
DIETARY_SUPPLEMENT
9
DIAGNOSTIC_TEST
7
PROCEDURE
5
RADIATION
3
Recruiting vs. Completed (2yr)
Recruiting
7058
Completed
3763
Competitive Landscape
Sponsor Classification
33%
67%
INDUSTRY (7)
OTHER (14)
Top Sponsors
SponsorTrialsClass
Novo Nordisk A/S3INDUSTRY
University of Kansas Medical Center2OTHER
ETH Zurich2OTHER
IRCCS Azienda Ospedaliero-Universitaria di Bologna2OTHER
Ottawa Hospital Research Institute2OTHER
M.D. Anderson Cancer Center1OTHER
Menoufia University1OTHER
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.1INDUSTRY
Centre for Addiction and Mental Health1OTHER
Odense University Hospital1OTHER
Bristol-Myers Squibb1INDUSTRY
Tameside General Hospital1OTHER
Cancer Institute and Hospital, Chinese Academy of Medical Sciences1OTHER
Oncoinvent Solutions AS1INDUSTRY
The Perfect Series Sdn Bhd1INDUSTRY
Geographic Distribution
Top U.S. States by Trial Density
StateTrialsTop City
Texas16Houston
California11Los Angeles
Florida9Tampa
Minnesota8Rochester
Pennsylvania7Pittsburgh
Massachusetts6Boston
New York6New York
Maryland4Baltimore
Michigan4Ann Arbor
North Carolina4Durham
Kansas3Kansas City
Colorado3Aurora
Washington3Seattle
New Hampshire3Lebanon
Virginia3Charlottesville
Wisconsin2Madison
Illinois2North Chicago
New Jersey2East Brunswick
Utah2West Valley City
Alabama2Birmingham
Expansion Intelligence
+264.8%
Discovery lift — trials found by semantic expansion that exact-match search misses entirely. This is the gap competitors don't see.
2
Exact
2
Parent
4
Related
3
Comorbid
5
Therapeutic
Top Expansion Terms
  • metabolic disease Parent
  • endocrine disorder Parent
  • type 1 diabetes Related
  • type 2 diabetes Related
  • insulin resistance Related
  • hyperglycemia Related
  • diabetic neuropathy Comorbid
  • diabetic retinopathy Comorbid
  • diabetic nephropathy Comorbid
  • GLP-1 receptor agonist Therapeutic

These terms are curated from clinical literature — not generated by a language model. Each captures trials that use variant nomenclature for the same underlying condition or therapeutic area.

Key Findings
What This Landscape Means for diabetes
high
Standard searches miss 265% of relevant trials for diabetes — semantic expansion across related conditions and therapeutic approaches is essential for complete landscape visibility.
5123 additional trials found via expansion vs 1935 exact matches
high
Phase 2 volume (18) significantly exceeds Phase 3 (3), indicating a pipeline bottleneck — most candidates are 2-4 years from potential approval.
Phase 2/Phase 3 ratio: 6.0x
medium
5 industry sponsors are actively competing in this space, signaling strong commercial interest and investment validation.
Top industry: Novo Nordisk A/S, CSPC Baike (Shandong) Biopharmaceutical Co., Ltd., Bristol-Myers Squibb
Next Steps
Take Action on This Intelligence
//
Stay Current
Get alerted when new trials open for diabetes and related conditions. Free tier monitors 1 condition weekly.
Set Up Alerts
[+]
Research Portal
Deploy this intelligence as your organization's permanent research hub — auto-updating, branded, zero hosting cost.
From $497
{<}
API Access
Integrate trial intelligence into your own tools. Full expansion engine, landscape analytics, real-time data.
View Plans
Top Recruiting Trials
20 actively recruiting studies
Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.
M.D. Anderson Cancer Center n=459 MD Anderson Cancer Center Houston, Texas
Eligibility Ages 18 Years
Contact Priyanka C Iyer, MBBS · (832) 291-6069 · piyer@mdanderson.org
Prospective Outcomes of Guided Equator Overdentures
Menoufia University n=40 Faculty of Dentistry Shibīn al Kawm
Intervention DEVICE: Fully guided static computer-assisted implant surgery (CAIS) for mandibular overdentures using Equator® attachments — Mandibular edentulism will be rehabilitated with implant-supported overdentures using a fully guided static computer-ass...
Eligibility Ages 40 Years – 70 Years
Contact Mohammed A. El-Sawy, PhD · 00201061314522 · Dr_sawy@windowslive.com
NCT06830343 PHASE1
The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. n=66 Peking University Third Hospital Beijing, Beijing Municipality
Intervention DRUG: SYH9017 — subcutaneous injection once time in SAD and four times in MAD
Eligibility Ages 18 Years – 60 Years
Contact Clinical Trials Information Group officer, / · 86-0311-69085587 · ctr-contact@cspc.cn
Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia
Centre for Addiction and Mental Health n=20 Centre for Addiction and Mental Health Toronto, Ontario
Intervention DRUG: Intranasal insulin — 160 IU insulin (Humalog) is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.
Eligibility Ages 17 Years – 45 Years
Contact Mahavir Agarwal, MD, PhD · 416-535-8501 · mahavir.agarwal@camh.ca
The Cardio-Metabolic Clinic
Odense University Hospital n=1600 Cardiovascular Research Unit, Odense University Hospital - Svendborg Svendborg, Region Syddanmark
Intervention OTHER: Cardio-Metabolic Clinic — The Cardio-Metabolic Clinic will adhere to a standardized evaluation and treatment program based on the latest treatment...
Eligibility Ages 19 Years
Contact Soeren Auscher, M.D, Ph.D · +45 6320 2402 · Soeren.Auscher@rsyd.dk
Transduction of Sympathetic Neural Activity in Human Obesity Without Hypertension
University of Kansas Medical Center n=60 University of Kansas Medical Center Kansas City, Kansas
Intervention DRUG: ascorbic acid — ascorbic acid
Eligibility Ages 18 Years – 79 Years
Contact Seth Holwerda · 9729223230 · sethholwerda@gmail.com
NCT07492680 PHASE2
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb n=260 Local Institution - 0096 San Francisco, California
Intervention DRUG: BMS-986504 — Specified dose on specified days
Eligibility Ages 18 Years
Contact BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
Convenient Home Access for Routine Monitoring in Diabetes (Charm-D Study)
Tameside General Hospital n=300 Tameside and Glossop Integrated Care NHS Foundation Trust Ashton-under-Lyne, Lancs
Intervention DIAGNOSTIC_TEST: HbA1c test — Patients will be asked to have a HbA1c test in the clinic with a venous draw and then either fingerprick or upper arm dr...
Eligibility Ages 18 Years
Contact Edward Jude, MD, FRCP · +441619224011 · edward.jude@tgh.nhs.uk
NCT06087068 PHASE2
Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=140 Cancer Hospital, Chinese Academy of Medical Science Beijing, Beijing Municipality
Intervention DRUG: Thyroxine — The treatment goal after lobectomy was to control TSH within the normal reference range (0.4-5 mU/L)
Eligibility Ages 18 Months – 70 Years
Contact jie liu · +861087787180 · liujie10-11@vip.163.com
Natural Course of Initially Metabolic Healthy Obese Individuals (Healthy Obesity)?
ETH Zurich n=300 dTIP / ETH Zürich Baden
Eligibility Ages 18 Years – 60 Years
Contact Jörg Goldhahn, Prof. · 044 633 70 54 · jgoldhahn@ethz.ch
NCT06504147 PHASE2
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Oncoinvent Solutions AS n=114 Moffitt Cancer Center Tampa, Florida
Intervention DRUG: Radspherin — Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224...
Eligibility Ages 18 Years, FEMALE only
Contact Anne-Kirsti Aksnes, PhD · 004722183305 · aksnes@oncoinvent.com
"Perfect Heartio" Drink and Cardiovascular Health
The Perfect Series Sdn Bhd n=55 UCSI University Cheras, Kuala Lumpur
Intervention DIETARY_SUPPLEMENT: Perfect Heartio Drink — Perfect Heartio (PH) drink is a nutritional drink composed of diluted herbal extracts of TCM, including ginger, Glycyrrh...
Eligibility Ages 18 Years
Contact Chung Keat Tan, PhD · 0175063305 · cktan@ucsiuniversity.edu.my
Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO/R1)
The First Hospital of Jilin University n=98 The First Hospital of Jilin University Changchun, Jilin
Intervention DRUG: Daphne Extract Capsules — The combination of Ruixiangsu capsules with the TC regimen for targeted maintenance therapy in epithelial ovarian cancer
Eligibility Ages 18 Years – 75 Years, FEMALE only
Contact Zhentong Wei Medic · 15804300686 · zhentongwei2009@163.com
Impact of Removable Cast Walker Design on Usability for Patients With Diabetic Foot Ulcers
Rosalind Franklin University of Medicine and Science n=40 Rosalind Franklin University of Medicine and Science North Chicago, Illinois
Intervention DEVICE: RCW design form — Tall RCW= a knee high removable cast walker with an offloading insole Short RCW= an ankle high (extending up the leg ju...
Eligibility Ages 18 Years
Contact Noah J Rosenblatt, PhD · 8475788425 · noah.rosenblatt@rosalindfranklin.edu
Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus
Cardenal Herrera University n=80 Francisco Javier Molina Payá Elche, Alicante
Intervention DIAGNOSTIC_TEST: SCORE2 — Will classify individuals into four cardiovascular risk categories: * For participants aged 50-69 years: * Low-to-mo...
Eligibility Ages 40 Years – 69 Years
Contact SERGIO MONTERO NAVARRO, PhD · +34965426486 · sergio.montero@uchceu.es
Effect of Artificial Sweetener (AFS) on Glucose Metabolism in Patients with Type 1 Diabetes (T1D)
McGill University Health Centre/Research Institute of the McGill University Health Centre n=25 Center for Innovative Medicine, The Research Institute of the McGill University Health Centre Montreal, Quebec
Intervention OTHER: Sweet taste perception with/without sweet taste blockade — In our study, we will use our four different novel flavored beverages, with and without a sweet taste blockade.
Eligibility Ages 18 Years – 45 Years
Contact Golnaz Arjmand, PhD · 514-398-3020 · golnaz.arjmand@mcgill.ca
NCT05983276 PHASE2
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
Loyola University n=40 Loyola University Medical Center Maywood, Illinois
Intervention DRUG: Decitabine — Decitabine is classified as hypomethylation agents. It works by helping the bone marrow produce normal blood cells and b...
Eligibility Ages 18 Years
Contact Patrick Stiff, MD · 708-327-3148 · pstiff@lumc.edu
Metabolic Biomarkers in Thoracic Cancers
University of Texas Southwestern Medical Center n=200 University of Texas Southwestern Medical Center Dallas, Texas
Intervention PROCEDURE: Imaging Biomarkers — Want to see if using 13C-glucose helps in detecting cancer and deciding on a treatment plan.
Eligibility Ages 18 Years
Contact Ebele Mbanugo, Ed.D, CCRP · 214-648-7097 · ebele.mbanugo@utsouthwestern.edu
NCT07634991 PHASE4
To Evaluate the Efficacy and Safety of N-acetyl Cysteine Administration in Patients With Diabetic Retinopathy
Ain Shams University n=76 National Institute of Diabetes and Endocrinology. Cairo
Intervention DRUG: N Acetyl cysteine, 1200mg (high dose) — N-acetylcysteine (NAC), alternatively referred to as N-acetyl-L-cysteine, is an acetylated version of the amino acid L-c...
Eligibility Ages 18 Years – 70 Years
Contact Nelly tarek Hegazy · 01010008548 · nelly.tariq@pharma.asu.edu.eg
Study of the Effects of Time-Restricted Feeding on the Immune Function of Individuals With Obesity
Assistance Publique - Hôpitaux de Paris n=24 HEGP - digestive surgery Paris
Intervention OTHER: Time-restrictred feeding — Time-restricted feeding pattern consisting of an 8 h eating window (from 6-8 am to 14-16 pm) followed by a 16 h fasting ...
Eligibility Ages 18 Years – 64 Years, FEMALE only
Contact Cléo BOURGEOIS · 0156095638 · cleo.bourgeois@aphp.fr